<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03454451</url>
  </required_header>
  <id_info>
    <org_study_id>CPI-006-001</org_study_id>
    <nct_id>NCT03454451</nct_id>
  </id_info>
  <brief_title>CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers</brief_title>
  <official_title>A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corvus Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corvus Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/1b open-label, dose escalation and dose expansion study of CPI-006, a
      humanized monoclonal antibody (mAb) targeting the CD73 cell-surface ectonucleotidase in adult
      subjects with select advanced cancers. CPI-006 will be evaluated as a single agent, in
      combination with ciforadenant (an oral adenosine 2A receptor antagonist), in combination with
      pembrolizumab (an anti-PD1 antibody), and in combination with ciforadenant and pembrolizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities (DLTs) of CPI-006 as a single agent and in combination with ciforadenant and with pembrolizumab.</measure>
    <time_frame>From start of treatment to end of treatment, up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events as assessed by NCI CTCAE v.4.03, of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab.</measure>
    <time_frame>From start of treatment to end of treatment, up to 36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identify the MDL(maximum dose level) of single agent CPI-006</measure>
    <time_frame>From start of treatment to end of treatment, up to 36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve (AUC) of CPI-006</measure>
    <time_frame>Day 1, 2, 8 , and 15 of Cycle 1 &amp; 4 (each cycle is 21 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum serum concentration (Cmax) of CPI-006</measure>
    <time_frame>Day 1, 2, 8 , and 15 of Cycle 1 &amp; 4 (each cycle is 21 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate per RECIST v.1.1 criteria of CPI-006 as single agent and in combination with ciforadenant and with pembrolizumab.</measure>
    <time_frame>From start of treatment to end of treatment, up to 36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">378</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <condition>Renal Cell Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Triple Negative Breast Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>Bladder Cancer</condition>
  <condition>Metastatic Castration Resistant Prostate Cancer</condition>
  <condition>Non-hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-006</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort1b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-006 + ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-006 + pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-006</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-006 + ciforadenant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CPI-006 + pembrolizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-006</intervention_name>
    <description>Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days until MTD is reached or until disease progression.</description>
    <arm_group_label>Cohort 1a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-006 + ciforadenant</intervention_name>
    <description>Subjects will receive escalating doses of CPI-006 administered intravenously once every 21 days in combination with CPI-444 orally twice daily until MTD is reached for CPI-006 or until disease progression.</description>
    <arm_group_label>Cohort1b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-006 + pembrolizumab</intervention_name>
    <description>Subjects will receive escalating doses of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until MTD is reached for CPI-006 or until disease progression.</description>
    <arm_group_label>Cohort 1c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-006</intervention_name>
    <description>Selected dose of CPI-006 administered intravenously once every 21 days until disease progression.</description>
    <arm_group_label>Cohort 2a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-006 + ciforadenant</intervention_name>
    <description>Selected dose of CPI-006 administered intravenously once every 21 days, in combination with CPI-444 orally twice daily until disease progression.</description>
    <arm_group_label>Cohort 2b</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CPI-006 + pembrolizumab</intervention_name>
    <description>Selected dose of CPI-006 in combination with pembrolizumab administered intravenously once every 21 days until disease progression.</description>
    <arm_group_label>Cohort 2c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

          2. Documented incurable cancer with one of the following histologies: nonsmall cell lung
             cancer, renal cell cancer, triple negative breast cancer, colorectal cancer with
             microsatellite instability(MSI), bladder cancer, cervical cancer, uterine cancer,
             sarcoma, endometrial cancer, and metastatic castration resistant prostate cancer.

          3. At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST
             1.1).

          4. For Escalation: At least 1 but not more than 5 prior systemic therapies for advanced/
             recurrent or progressing disease. For Expansion: Subject must have progressed on, be
             refractory to, or intolerant to 1-3 prior systemic therapies.

          5. Willingness to provide tumor biopsies.

        Exclusion Criteria

          1. History of severe hypersensitivity reaction to monoclonal antibodies.

          2. Subjects who have received prior therapy with regimens containing
             cytotoxicT-lymphocyte antigen-4 (CTLA-4), programmed cell death ligand 1 (PDL1), or
             PD1 antagonists are NOT permitted to enroll unless all adverse events (AEs) while
             receiving prior immunotherapy have resolved to Grade 1 or baseline prior to screening.

          3. History of (non-infectious) pneumonitis that required steroids or subject has current
             pneumonitis.

          4. The use of any investigational medication or device in the 30 days prior to screening
             and throughout the study is prohibited.

          5. Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S Mahabhashyam, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Corvus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Sudhir Manda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City Of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Sumanta Pal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Fong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>203-785-3482</phone>
      <email>ycci@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia LoRusso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>305-243-0865</phone>
      <email>txl351@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jaime Merchan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Sosman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Walter Stadler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The John Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Kristen Marrone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Toni Choueiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Nicholas Vogelzang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology, P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Garbo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Igor Puzanov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Igor Puzanov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>212-824-7309</phone>
      <email>ccto@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Thomas Marron, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina BioOncology Institute</name>
      <address>
        <city>Huntsville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>704-947-6599</phone>
      <email>info@carolinabiooncology.org</email>
    </contact>
    <investigator>
      <last_name>John Powderly</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>dstrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>David Waterhouse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma - Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>405-271-1112</phone>
      <email>SCC-Clinical-Trials-Office@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Abhishek Tripathi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>dstrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Jason Luke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prisma Health Cancer Inst - Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>Dstrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Ki Chung</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>615-329-7274</phone>
      <email>asksarah@sarahcannon.com</email>
    </contact>
    <investigator>
      <last_name>Melissa Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Cancer Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>972-566-3000</phone>
      <email>information@marycrowley.org</email>
    </contact>
    <investigator>
      <last_name>Minal Barve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Spira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Coordinator</last_name>
      <phone>414-805-8900</phone>
      <email>CCCTO@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Matthew Riese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Lisa Horvath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Amy Prawira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Rina Hui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Brett Hughes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D Strahs</last_name>
      <phone>650-900-4518</phone>
      <email>DStrahs@corvuspharma.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin Markman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 5, 2018</study_first_submitted>
  <study_first_submitted_qc>March 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 6, 2018</study_first_posted>
  <last_update_submitted>February 12, 2020</last_update_submitted>
  <last_update_submitted_qc>February 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>RCC</keyword>
  <keyword>TNBC</keyword>
  <keyword>mCRPC</keyword>
  <keyword>CRC</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Kidney Cancer</keyword>
  <keyword>Rectal Cancer</keyword>
  <keyword>Breast Cancer</keyword>
  <keyword>Sarcoma</keyword>
  <keyword>Endometrial</keyword>
  <keyword>Pancreatic</keyword>
  <keyword>Ovarian</keyword>
  <keyword>SCCHN</keyword>
  <keyword>NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

